A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF LP352 IN THE TREATMENT OF SEIZURES IN CHILDREN AND ADULTS WITH DRAVET SYNDROME

Registry ID

LP352-302

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

LONGBOARD PHARMACEUTICALS, INC.

Start date

2025-07-01

Last update

2025-01-30

Conditions

• DRAVET SYNDROME

Related clinical trials

• A 20-WEEK MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF EPX-100 (CLEMIZOLE HYDROCHLORIDE) AS ADJUNCTIVE THERAPY IN CHILDREN AND ADULT PARTICIPANTS WITH DRAVET SYNDROME (ARGUS TRIAL)
• CANNABIDIOL IN CHILDREN WITH REFRACTORY EPILEPTIC ENCEPHALOPATHY: A PHASE 1 OPEN LABEL DOSE ESCALATION STUDY

View on source registry